



Produced and hosted by  
The Swedish Life Science Industry Organization  
**swedenBIO**

# Nordic Life Science Days 2014

Invest – Partner – Network  
7-9 September | Stockholm Waterfront

Featuring European Cancer Cluster Partnering



## ECCP Co-Host



## NLSDays Co-host



## Premium Sponsor



## Platinum Sponsor



# Welcome to Nordic Life Science Days!

Or Welcome back! Whether you are a first time visitor or a returning delegate, you are now part of a growing community focused on business opportunities in Nordic life science. Last year we grew our annual investment day into a broader Nordic event. We did so based on a strong belief that the Nordic region offers a scale and diversity that surpasses its member countries.

The immediate success showed that we sure were on the right track. With 650 delegates and 123 licensing opportunities, we knew that we had created an important meeting point for the Nordic and global life science industry. This year's number shows that it was just the beginning.

You are now some 800 delegates and there are, when writing this, 330 licensing opportunities in the partnering system!

This year we are proud to integrate the European Cancer Cluster Partnering conference (ECCP) as a special oncology track. This is made possible through close cooperation with Oslo Cancer Cluster and Toulouse Cancer-Bio-Santé Cluster. A collaboration that shows how new contact points can be created when creative and determined minds come together. We hope that you will find your next partner in the same way during these days. Make sure to use the partnering system and the many meeting points set up during the conference!

Speaking of partners, we want to thank all our co-hosts and sponsors for the important support that makes this meeting possible.

On behalf of SwedenBIO and our co-hosts, we welcome you to a fruitful meeting and hope to see you again at Nordic Life Science Days in September 2015!

Welcome!  
Välkommen!



Jonas Ekstrand  
CEO SwedenBIO



Olivier Duchamp  
Managing Director, NLSDays



## Conference Supporters





---

Producer and host



## SwedenBIO – helping innovative companies succeed!

SwedenBIO is the national trade association for the life science industry in Sweden. The organization is member driven, private, non-profit and was founded in 2002. Our vision is to help create a world leading life science industry in Sweden.

Our main objective is to strengthen our members and enable them to develop new innovative treatments, devices and diagnostics that will improve health across the world. As a member, you join a network of professionals and take part in Sweden BIOs advocacy.

We create meeting points where individuals and organizations can meet, exchange knowledge and form new ideas. Our largest annual meeting is Nordic Life Science Days, an event that helps market Nordic life science and brings business and investors to the region.

We also have a continuous dialog with the government and society to create visibility and interest for Swedish Life Science, thereby lending support to the development of a successful industry.

[www.swedenbio.com](http://www.swedenbio.com)



---

Co – Host



## Biopeople

Biopeople is Denmark's life science cluster. Biopeople is part of the Danish infrastructure for innovation established and cofunded by the Ministry of Higher Education and Science. We have an international outreach that helps Danish companies and researchers to establish cross border collaborations and vice versa.

Biopeople embraces and gathers the vast majority of public and private research within health and life science in Denmark. The network includes all relevant Danish universities, research institutions and hospitals plus the Danish Health and Medicines Authority. On the private side, industry associations contribute their resources, and we have numerous pharma, medtech, food and biotech companies as members of Biopeople.

Our aim is to stimulate innovation through activities that bring researchers and stakeholders together across disciplines, sectors and public-private boundaries. We help academia and industry to co-create and develop ideas into new projects, products and services to benefit global health and welfare.

---

Co – Host



Cancer-Bio-Santé  
CLUSTER

---

## Cancer Bio Santé

In the context of the French Government initiative to create competitiveness clusters, the Cancer-Bio-Santé Cluster was formally approved on 12 July 2005. It is the only French cluster dedicated to innovation in the field of cancer and ageing.

The cluster was created to provide support for more than 200 companies in the Midi-Pyrénées and Limousin Regions, working in collaboration with research laboratories, cancer centers and hospitals, to develop innovative products for cancer treatment and monitoring of ageing people.

The Cancer-Bio-Santé Cluster targets a multidisciplinary approach and operates throughout the value chain covering the landscape of cancer, from prevention (food /environment related risk factors) to diagnostic, therapy, follow up and home care.

The Cancer-Bio-Santé Cluster covers four Strategic Activity Fields:

- Prevention and food
- Molecules/Therapeutics
- Technological innovations
- Home support services

---

Co – Host



---

## HealthCapital

The Healthcare Industries Cluster Berlin-Brandenburg – HealthCapital – is one of the leading life sciences and healthcare centers in the world. The unique research and clinic landscape, which is the region's major strength, is supported by a close network of key players from industry, start-ups, finance, clinics and politics.

Here, numerous technology parks and networks in different fields, above all biotechnology and medical technology, create an excellent infrastructure for transforming the latest scientific findings into innovative products and services for the healthcare sector.

Berlin Partner for Business and Technology is responsible for managing the cluster together with ZAB Brandenburg Economic Development Board.

---

Co – Host

medicon valley alliance

Creating Opportunities

---

## Medicon Valley Alliance - an organization for the entire life science community in Medicon Valley

MVA is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley. Our members represent the region's triple helix and include universities, hospitals, human life science business, regional governments and service providers.

We exist to make Medicon Valley an attractive destination for the best talent within life science. We do this because talent is the single most important and valuable resource in a knowledge-intensive sector such as life science.

We create value for our members by launching and driving initiatives that put Medicon Valley firmly ahead in the global race for talent. This ensures our members access to a steady pool of highly skilled workers, who can help them grow and compete successfully in today's global marketplace. Our vision is to release the full potential of Medicon Valley.

---

Co – Host



---

## Oslo Cancer Cluster: A dedicated oncology cluster

Oslo Cancer Cluster is an oncology research and industry cluster dedicated to accelerating the development of new cancer diagnostics and medicines. We gather almost 70 members from Norway and Northern Europe representing the entire oncology value chain.

As a Norwegian Centre of Expertise, the Norwegian government partially funds the cluster. An evaluation from 2013 states that Oslo Cancer Cluster is a strong biotech cluster well positioned in the global oncology industry.

Oslo Cancer Cluster has core expertise in the field of Immuno-Oncology. The cluster is building an exciting pipeline of novel cancer immunotherapies in preclinical and clinical development.

In 2015 we open the Oslo Cancer Cluster Innovation Park, next door to the Norwegian Radium Hospital and the Institute of Cancer Research at Oslo University Hospital. Here we will host a specialized oncology incubator.

For more information:

[www.oslocancercluster.no](http://www.oslocancercluster.no) // [www.occinnovationpark.com](http://www.occinnovationpark.com) // [www.occincubator.com](http://www.occincubator.com)

---

Co – Host



---

## About STING, Stockholm Innovation & Growth

About STING (Stockholm Innovation & Growth) STING's vision is to contribute to the building of new global growth companies by attracting the best innovators and entrepreneurs within ICT, Internet/media, Life Science and Cleantech. Our incubator and accelerator programs provide support within business development, financing, recruitment and networks, and we help you to create the right conditions for your company to conquer the world.

STING has supported over 100 startups over more than 10 years and have gained a lot of valuable experience in how to succeed. As a STING company, you get support from experienced business coaches who themselves are entrepreneurs and have previously built their own companies. Accepted teams work side-by-side with Stockholm's most promising entrepreneurs in a high-paced environment where the companies of the future evolve and grow.

More information: [www.stockholminnovation.com](http://www.stockholminnovation.com)



---

Co – Host



---

## Finnish Bioindustries FIB is Finland's biotechnology industry association, established in 1997.

It is a private, independent non-profit organisation. Member companies represent all life science areas, from health care and functional food to biomaterials.

Finnish Bioindustries encourages the utilization of modern biotechnology in products, manufacturing processes and services and promotes entrepreneurship based on modern biotechnology according to the principles of sustainable development.

Finnish Bioindustries promotes national and international networking and information transfer between the different players in the field.

Finnish Bioindustries participates in national and international technology programs, actively exploits finance systems and promotes technology transfer. One of the main tasks is to help the work of commercializing new areas of biotechnology. Start-up hi-tech companies have the opportunity to share their experience and problems with each other using the platform provided by Finnish Bioindustries.

Finnish Bioindustries also supports national and international cooperation for the preparation and surveillance of biotechnology legislation.

[www.finbio.net](http://www.finbio.net)



---

Co – Host



---

## Life Science Nord – together for innovative medicine

The two North German states of Schleswig-Holstein and Hamburg stand out for their broad base of companies and for the presence of a complete value chain in the life sciences.

Under the umbrella of Life Science Nord, the cluster agency Life Science Nord Management GmbH and the Life Science North e.V. association work together towards the goal of further developing the Hamburg and Schleswig-Holstein region into an internationally leading Life Science Network.

The cluster agency Life Science Nord Management GmbH initiates strategic projects and supports the promotion of companies, science and institutes with an emphasis on innovative medicine. It connects business and research in the north, thereby bringing to companies the expertise from universities and research facilities as well as its network of close contacts. Additionally, the management is responsible for representing the regional life sciences on national and international levels.

[www.lifesciencenord.de](http://www.lifesciencenord.de)

---

### Karin Aase



Karin Aase holds a PhD in molecular biology from the Karolinska Institutet. Karin was an assistant professor at Cancer centre Karolinska until she joined SwedenBIO in 2007, where her first mission was to establish the EU-support office where small and medium-sized enterprises (SMEs) could get free-of-charge support. She later joined the core team of SwedenBIO being in charge of the scientific, patent and clinical trials working groups. In 2011 Karin started at VINNOVA where she focuses on public funding for SMEs, both national and European.

---

### Saharla Ahmed



Saharla joined the Wellcome Trust in 2007 and is responsible for cultivating early-stage funding opportunities, project managing the Trust's interests in a portfolio of healthcare projects and coordinating the Division's IP portfolio. Before joining the Trust, she worked as a Patent Analyst at Thomson Scientific, specializing in patent searching and patent-based intelligence for the pharmaceutical industry. Saharla holds a BSc in Genetics and an MSc in Intellectual Property Law, both from Queen Mary, University of London.

## SPEAKERS

---

Mohammed Amarzguioui

Mohammed Amarzguioui has a PhD in Molecular Biology from University of Oslo (2003). Following postdoctoral training at an applied research lab in City of Hope, California, he served as Research Director for SiRNAsense A/S (2006-2010), a preclinical therapeutic development company within the field of RNA interference, with a focus on oncology. He was responsible for management of the company's R&D activities, as well as contributing to IPR management. In 2011 he joined Inven2, the technology transfer office of The University of Oslo and Oslo University Hospital, as Technology Strategy Manager. His responsibility is evaluating submitted innovations and management of established commercialization projects, particularly within oncology therapy and diagnostics.

---

Anne Zahle Andersen

Following a PhD in computational biochemistry and an industrial postdoc in the area of food decontamination, I worked 2 years as with outreach and process activities at the Department of Biochemistry and Molecular biology at University of Southern Denmark. As business scout and development manager at University of Southern Denmark, I now use my strong scientific background and communication skills to facilitate the exchange of knowledge and technologies between Researchers at the Faculty of Science and our Partners in industry.

---

### Øyvind Kongstun Arnesen



Øyvind Kongstun Arnesen CEO MD with 10+ years of experience from pharma industry with positions as Medical Director Norway (Bristol-Myers Squibb), Medical Director and Head of Clinical Operations Nordic countries in Boehringer Ingelheim. Member of The National Commission for the Investigation of Research Misconduct in Norway. Board Member of the Norwegian Pharmaceutical Industry Association

---

### Ylva Berg



Ylva Berg was appointed CEO of Business Sweden April 1, 2014.

She served most recently as the Managing Director of the Nordic region at Dassault Systèmes.

With over 15 years of experience in senior management positions in publicly traded and global companies, she possesses great knowledge of the Swedish private sector and has extensive experience in building successful organizations.

## SPEAKERS

---

### Elisabeth Björk

Elisabeth is the VP CVMD GMed – the Head of late phase Cardiovascular and Metabolic development unit within AZ. She is leading the development activities across the AZ late phase cardiovascular (mainly Brilinta, Crestor and Epanova), diabetes (mainly Onglyza, Forxiga, Byetta, Bydureon and combinations) and CKD (roxadustat and tenapenaror in development) portfolio.

Prior to taking on this role in June 2012, Elisabeth was Global Product VP for dapagliflozin (approved as Forxiga in Europe and many other countries, including Australia, and as Farxiga in the US), and led the development of this first-in-class drug in partnership with Bristol Myers Squibb. She has also been involved in the delivery of key late phase CVMD and GI projects like Crestor, Nexium, Onglyza, Brilinta and others. She led the team that delivered several CV outcomes studies for Crestor (CORONA, JUPITER, AURORA).

Elisabeth has a passion for patients and science, with a special focus on CV outcomes trials, as well as for developing people and teams and inspire them to achievements they did not think were possible. Elisabeth herself is on a constant learning curve and enjoys doing things she has never done before.

Elisabeth is an endocrinologist by training and an associate professor of medicine at Uppsala University, and was Head of the Diabetes and Endocrinology Unit at the University Hospital, Uppsala, where she spent 15 years in clinical practice and diabetes research, before joining AZ in 2002.

---

### Magnus Björsne



Magnus Björsne Executive Director, AstraZeneca BioVentureHub.

Magnus Björsne is responsible for the AZ BioVentureHub, an initiative that aims to strengthen the ecosystem in Scandinavian Life Science by offering small pharmaceutical company access to AstraZeneca's infrastructure and expertise. Before this, Magnus served as Business Development Transaction Director with a focus on identifying, evaluating and acquiring projects and companies. Magnus is also Director of the Board of SwedenBIO, the Swedish Life Science Industry Organization.

---

### Maria Bobadilla



Maria Bobadilla holds an MD and PhD degree and obtained a Master certificate in Project management, by the George Washington University. Maria has more than 20 years' experience in drug development gained at different large pharmaceutical companies. All over these years she hold different positions of increasing responsibility, developing expertise in preclinical safety, discovery, early development, translational medicine and biomarkers. Since 2006, Maria works for F. Hoffmann La Roche. She currently has a position as Senior Director at Roche Partnering, where she is responsible for the Extending Innovation Network (EIN) Program in Europe. This Program aims at accessing open innovation through partnerships with leading academic institutions and startup companies.

Maria has co-authored more than 30 peer reviewed publications with several patents also filed.

---

### Nils Bohlin



Mr. Nils Bohlin is a Managing Partner with Arthur D. Little. He is a co-founder of the firm's activities in Sweden. Based in the Stockholm office he leads its Global Life Science practice.

His work includes corporate and business unit strategy, organisation design and development, business planning for large, medium and small companies in the Life Science sector.

He is engaged in the development of regional clusters in biotechnology.

He is co-author of the international best sellers Third Generation R&D, The Innovation Premium. He led the work on the book; "Växa Snabbare" advocating an international growth approach through regional clusters.

He holds an MBA from INSEAD, a M.Sc. in Chemical Engineering from Chalmers and a Bachelor of Humanities from the University of Gothenburg.

## SPEAKERS

---

**Carl Borrebaeck**


Vice President Carl Borrebaeck received the first chair as professor of Immunotechnology in Scandinavia 1989. His main research interests are cancer proteomics, for early detection and prognosis, and antibody engineering, for the generation of human therapeutic antibodies. He is a permanent member of the Royal Swedish Academy of Engineering Sciences. He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy, the Research! Sweden Award 2012 for his medical research of value for patients and health organizations, and the Royal Academy of Engineering Sciences Gold Medal 2012 for outstanding contributions to biomedical science. He is the Vice President of Lund University since 2009, responsible for innovations and industrial collaborations.

---

**Peter Braun**


Peter E. Braun has over 20 years of experience as a serial entrepreneur as well as in various senior and top management positions in the aerospace (Airbus group) and automotive industries (Daimler). He has successfully launched two industrial companies and two finance-related enterprises.

As a founder and entrepreneur, he completed two IPOs, one in the United States and one in Germany. And accompanied several others. During his career, Peter gathered profound knowledge of the capital markets and the finance sector with activities in Germany, Switzerland, Luxembourg, Canada, USA and Asia. He is a much sought after coach for start-ups, a compelling speaker and a highly demanded senior advisor and board member. In his most recent activity as a Co-Founder and CEO of the Mountain Club AG, he created a peerless e-banking solution for business angel and private equity investments in collaboration with the strategic partner UBS AG.

Peter E. Braun is an active board member at EBAN, The European Trade Association for Business Angels, Seed Funds and other Early Stage Market Players ([www.eban.org](http://www.eban.org)) in Brussels. As one of the experts of the Swiss Top 100 Start-ups, he has invested in over 40 companies with his investment structure. Peter has also build a vast network in the MedTech and Biotech investment circles.

---

## Charlotte Brogren



Director General of the Swedish Governmental Agency for Innovation Systems, VINNOVA.

Charlotte Brogren joined VINNOVA as Director General on September 1st 2009. Before joining VINNOVA she worked for 15 years for the global electrical company ABB in various management positions within research & development, most recently, as Technology Manager for ABB's Robotics Division. She has a PhD in Chemical Engineering from the University of Lund. Charlotte Brogren is chairman of the board of the Swedish Industrial Development Found and holds several other board positions. Since 2005 she is a member of the Royal Swedish Academy of Engineering Sciences and since 2011 a member of the council board of the International Electro-technical Commission.

---

## Cristian Capasso



Cristian Capasso is a PhD student in the ImmunoViroTherapy Lab at University of Helsinki (IVTLab; [www.ivtlab.com](http://www.ivtlab.com)). Cristian has gotten his bachelor degree in immunology at the University of Naples and his Master degree in Biotechnology at the Center of Genetic Engineering (CEINGE) in Naples supervised by professor Lucio Pastore. After his master Cristian has joined the IVTLab lead by professor Vincenzo Cerullo for his PhD studies. The IVTLab focuses its research on developing personalized anti-cancer vaccines. Together with his supervisor Cristian has developed a novel approach for anti-cancer vaccines called PeptiCrad.



## SPEAKERS

## Johan Christenson



Partner of HealthCap. Prior to joining Odlander Fredrikson in 2001. Dr Christenson was with SEB Företagsinvest (the venture capital arm of SEB) to supervise the health care portfolio.

He has senior management experience from Astra Pain Control as Project director and AstraZeneca as Global Product Director and member of the global therapy area management team of Pain & Inflammation. He received his medical training at the Karolinska Institute and published his thesis in 1991 rendering him a Ph.D. in basic neuroscience. He served as a lecturer in neuroscience and is the author of 17 scientific articles. He held a position as assistant dean at the Karolinska Institute Graduate school for two years. Dr Christenson has four years of clinical specialist training in pediatrics and pediatric neurology.

## Erwan Corcuff



Erwan Corcuff was Engineer and project manager at the "Institut Pasteur" (Paris, France) during 15 years where he developed new humanized mouse models in the fields of Immunology and Infectiology.

Since 2010, he is one of the Co-founders and the CEO of the company AXENIS, spin off of the Pasteur Institute.

AXENIS is a service company using humanized mice as preclinical models in immunology, for the pharmaceutical industry, biotechnology companies and academic research.

Erwan Corcuff holds two Master degrees in Science and Technology, Curriculum supplemented by entrepreneurial training business schools: HEC (2008), the EMLYON (2009) and Boston University (2010).

Awards:

Best Bplan, HEC Foundation 2008.

National competition of emerging company 2009.

NETVA, Boston University 2010

Paris Innovation 2011.

---

### Marc Van de Craen



Marc Van de Craen is active in the biotech industry for more than 24 years. He received his Ph.D. at the University of Gent (Belgium) and was director at Devgen N.V. (Currently Syngenta) where he headed different departments with one team based in Singapore. Additionally he acted as consultant for different biotech companies. In 2009 he created a partnership, BiotechSubsidy, focusing on optimizing the subsidy management of biotech and pharma companies. This partnership was granted over 60 million EURO subsidy.

---

### Jean-Pol Detiffe



Jean-Pol Detiffe, OncoDNA's CEO, is a Université Catholique de Louvain (UCL) pharmacy graduate.

He graduated as a pharmacist in 1995, and an industrial pharmacist/Qualified Person in 1997. He has an MBA from the Louvain School of Management. He creates his first DNA sequencing company, in 2004 DNAVision.

Jean-Pol Detiffe was elected 'Manager of the year' for the Charleroi region. In 2007 his company got the Walloon prize for Technological Innovation and also first prize in the 5th edition of Enterprize. In February 2012, Jean-Pol Detiffe left the company he had created – it had been bought in 2010 by a French investor – and in November 2012 set up OncoDNA. Its investors are IPG (Institute of Pathology and Genetics, Sambrinvest and different personalities, like Jean Stéphenne, ex-CEO of GSK Vaccines, who invested in a personal capacity in the young company, François Blondel, CEO of KitoZyme and ex-CEO of IBT).

## SPEAKERS

---

Tanja Dowe

Tanja Dowe is the Managing Partner of Innomedica Ltd, Europe's leading strategy consulting company focused on pharmaceutical and medical technology markets.

Ms. Dowe has more than 15 years of experience in building business strategies, analyzing markets & transaction targets, and in-/out-licensing. Having personally worked with over 80 life sciences companies in 130+ business development projects, Ms. Dowe has acquired substantial knowledge in business models and market requirements necessary to commercialize innovations in the life science markets. Prior to Innomedica she worked in market analyst positions in North America and started a market analysis company in Finland, that later merged with Innomedica.

Ms. Dowe has a MSc in microbiology & biochemical engineering.

---

Fouad Eddhari

Dr. Fouad Eddhari is the Scientific Liaison Officer of ImmuneHealth, a CRO located in Gosselies (Wallonia – south region of Belgium) providing support to pharma companies (vaccines/cell therapy evaluation and the development of diagnostics assay with the discovery/validation of immunological biomarkers) and working among others with GSK Vaccines. As a research center for Walloon health actors, ImmuneHealth develops many partnerships with regional actors.

Dr. Eddhari is responsible for interactions with companies to develop R&D projects with ImmuneHealth. Graduated in Life Science, Dr Fouad Eddhari completed his PhD thesis in the laboratory of immunology at IBMM, the Institute of Biology and Molecular Medicine from Université Libre de Bruxelles (ULB). During this work, he was also implicated in a collaborative research agreement awarded by GSK, developing in vitro assays to better assess vaccine efficacy.

---

### Anders Ekblom



Anders Ekblom has extensive experience as an executive and leader with broad business knowledge from senior roles in the biopharmaceutical industry.

During 19 years at AstraZeneca Anders was a member of global executive teams holding different senior roles including Executive Vice President Global Drug Development, EVP Global Medicines Development, Global Head Clinical Development, Global Head Science and Technology Integration, and CEO AstraZeneca AB Sweden.

Anders is a board certified MD (anesthesiology and intensive care), PhD, DDS and Associate Professor at Karolinska Institutet, Stockholm, Sweden. He has 60 scientific publications in peer reviewed journals. He is currently a Senior Advisor to Phase 4 Partners, UK, Director of the Board of the Karolinska University Hospital, SwedenBio and some Biotech companies.

---

### Jonas Ekstrand



Jonas Ekstrand got his Ph.D. from Karolinska Institutet and Ludwig Institute for Cancer Research in 1991, writing his thesis on the molecular biology of brain tumours. In the 90's he worked as a researcher and lecturer at universities in Canada, USA and Sweden. He has nearly 20 years of pharma industry experience with operational and strategic roles as an Associate Director at AstraZeneca, Director of Biology and Molecular Sciences at Medivir AB, CEO of Actar AB, co-founder and CEO of AlzeCure Foundation and AlzeCure Discovery AB. Jonas is currently Director General of Sweden-BIO, the Swedish Life Science Industry Organization. When not in his office, he can be found watching birds in remote areas.

## SPEAKERS

---

Jesper Eriksson

I love changing peoples perspectives (including my own). Why do we act the way we do? How do we perceive ourselves and how do others perceive us? What words do we use to describe people, groups and actions? To what extent are we using the history when we are trying to create new things?

I am a Certified Master Black Belt and am currently working as an Operational Excellence Specialist with the transformation of the Pfizer Strängnäs Site. I have previously been working as a process specialist for the manufacturing of biopharmaceutical drug substances and have also been a project team leader for the development of manufacturing processes.

I hold a Ph. D. in Genetics from Stockholm University.

---

Maria Fagerquist

Maria Fagerquist is the Deputy Director General of LIF - The Swedish Association of the Research-based Pharmaceutical Industry. Ms. Fagerquist joined LIF this August from Novartis Oncology where she was Head of European Public Affairs, focusing also on policy work related to Rare Cancers and Personalised Medicine.

Ms Fagerquist holds a Master of Medicine from the University of Uppsala and an Executive Master in Business Administration from the Stockholm School of Economics. She has performed research in the field of neuropsychopharmacology at the Karolinska Institute and has worked several years in clinical trials management. Ms Fagerquist has also worked at TLV, the Swedish Pricing and Reimbursement Authority.

---

### Staffan Folin



Staffan Folin is a partner with EY and is responsible for EY's Life Sciences sector in the Nordics. He is also responsible for EY's corporate finance practice in the Nordic region. As such, he is a seasoned M&A practitioner with vast experience from more than 100 transactions across many different sectors but in particular the Life Sciences and Healthcare sectors. Staffan's experience includes advising public and private companies in merger acquisitions, disposals and fund raising transactions. His experience also includes valuations, fairness opinions, business plan advice and coordinating due diligence projects.

Staffan has a Master of Science from the Stockholm School of Economics.

---

### Dennis Ford



Dennis Ford is an entrepreneur, author, and thought leader with expertise in sales, marketing, and business development. He has spent most of his career launching new companies and developing a market for nascent game-changing technologies. In recent years, he has worked extensively with global alternative investors interested in high-growth early stage technologies. He is a big proponent of using profiling and matching technology to find that all-important business fit in the marketing and selling process.

Ford is the author of *The Peddler's Prerogative* and *The Fund Manager's Marketing Manifesto*, two well-received sales and marketing books. His latest book is *The Life Science Executive's Fundraising Manifesto*. Ford also teaches Entrepreneurship Sales & Marketing course at the University of Massachusetts Boston.

---

## Jean-Jacques Fournie



Directeur de Recherches Classe Exceptionnelle au CNRS, biosketch:

1986: PhD thesis in Chemistry-Biochemistry, Université Toulouse 3 (Univ. Paul Sabatier)

1988-1989: Post-doc fellowship at CIRC (Garvan Institute), Sydney Univ. Australia (Immunology)

1999: Founder of Innate Pharma, S.A.S. ("the innate immunity company")

2003: Founder of ONG: "Universités du Monde"; member of university life sciences board (64 and 65)

2006: Head of Immuno-Oncology team "Innate Immunity, Malignant Hemopathies & Cancer Therapies", INSERM

2008: Co-organizer of the 11th world congress on gamma delta lymphocytes, Marseille, France

2010: Director of the « Centre de Recherches en Cancérologie de Toulouse » (225 persons),

Scientific director of Institut Universitaire du Cancer (IUC)-Toulouse Oncopole.

2012: Member and co-director of Laboratoire d' Excellence "Toulouse-Cancer", Member and co-director of Projet Hospitalo-Universitaire en Cancérologie "CAPTOR"

---

## Jan Fjellström



Partner and Co-Founder, ScientificMed

ScientificMed develops an innovative product concept where pharmaceuticals, medical devices, and m-health are used together to achieve improved treatment outcomes and increased safety. Jan's focus is how Behavior Change Techniques and User Experience in m-health can positively affect a patient's health outcome.

Prior to joining ScientificMed, Jan worked with strategy, business and product development for the e-health company CircadianQ. He began his career in IT and management consulting with Andersen Consulting (now Accenture).

Jan holds a Master's in Engineering Physics and a Bachelor's in Business Administration and Economics, both from Uppsala University.

---

## Anand Gautam



Anand Gautam has a strong background in scientific and commercial management of international research at various Biotechnology companies and academic institutions. Anand completed his PhD from the University of London in 1990 followed by post-doctoral training at Stanford University, California, USA. Anand was then appointed a Research Fellow and later a Leader at John Curtin School of Medical Research, The Australian National University (ANU); and was also appointed as an Associate Professor at Centre for Immunology and Cancer Research, University of Queensland, Brisbane.

For the past five years, as a Director of Innovation Sourcing, Anand Gautam has been responsible for Biopharmaceutical Innovation Scouring and strategies at Novo Nordisk, to help bring-in novel biologics to treat autoimmune diseases with special focus in Asia and Europe.

---

## Thomas Helleday



Professor Thomas Helleday received his PhD in Genetic Toxicology and a separate BSc in Business Administration and Economics from Stockholm University, Sweden. Being 35 years old, he received his third professorship at University of Oxford and a chair in cancer therapeutics, after demonstrating the synthetic lethality concept for targeting BRCA mutated cancers with PARP inhibitors.

Professor Helleday is currently the Torsten and Ragnar Söderberg Professor in Translational Medicine and Chemical Biology at Karolinska Institutet, SciLifeLab, where his research covers both basic and translational work including academic-driven clinical trials, based on scientific findings in his laboratory.

Professor Helleday has been awarded numerous eminent international grants and prizes, for instance the Eppendorf-Nature Young European Investigator Award (2005) and ERC advanced grant.



## SPEAKERS

## Ylva Hultman



Ylva Hultman is a Business Development Manager at The Stockholm Business Region Development, City of Stockholm, Sweden. Ylva holds a degree of Master of Science in Business and Economics. In addition, she has taken courses in Finance for Startups, Stockholm School of Economics, and Medicine for Decision makers, Karolinska Institutet. Ylva is a seasoned inward investment manager and has been working with several (more than 100) investments into the greater Stockholm region. The last years her investment focus has been on the Hotlist, which is a tool to assist foreign investors. When Ylva is not focused on investments she can be found on the board of the childhood diabetes foundation or sailing the Stockholm archipelago.

## Jan-Olof Jacke



Current positions in AstraZeneca  
R&D Finance Head  
President of AstraZeneca AB

Career/Previous positions

Sales and marketing roles in small family owned business.

Management consultant in a boutique consultancy firm.

Finance roles in AstraZeneca since 1999 spanning R&D, Commercial Business Development and Corporate.

Significant involvement in restructuring and strategic change programs.

Education

Master's degree from Gothenburg school of Economics and Commercial Law. Degree in Business and Administration with focus on Management and Management Accounting.

---

### Christian Jonasson



Christian Jonasson holds a M.Sc. in Pharmacy from the University of Uppsala in Sweden and a Ph.D. from the Department of Clinical Medicine, University of Bergen in Norway. Christian has over 20 years of experience from the life science sector including positions in the public sector, pharmaceutical industry and academia. He has had a long career in AstraZeneca spanning from clinical development to medical affairs, where he has held both expert roles and senior level management positions. He is now the Chief Scientific Officer of Lifandis AS, Norway, where he is responsible for the scientific delivery of industry-sponsored research projects within areas of epidemiology, biomarkers and drug discovery utilizing Norwegian biobanks and registries.

---

### Bertil Jonsson

---

### Eric Karran



Dr Eric Karran is a molecular biochemist by training, with a particular interest in enzymology and proteinases.

He has spent most of his career in the pharmaceutical industry, leading and managing multi-disciplinary drug discovery teams. He has held Chief Scientific Officer and Vice President roles in a number of companies, including SmithKline Beecham (now GSK), Pfizer, Eli Lilly and Johnson and Johnson.

Eric has specialized in Neuroscience research, and particularly Alzheimer's disease, for the past 20 years, participating in a number of projects that have led to late-stage clinical programmes. Eric is an author on some 60 scientific publications. Eric is a Visiting Professor in the Department for Human Genetics at the Catholic University of Leuven, Belgium, and an Honorary Senior Research Associate in the Department of Molecular Neuroscience at the Institute of Neurology, University College London. He is currently the Director of Research for Alzheimer's Research UK and has responsibility for strategic scientific direction.

## SPEAKERS

---

Petrus Laestadius


Petrus Laestadius joined Swedish Medtech in 2012 as Executive Vice President. Prior to his current role Mr. Laestadius has held various positions of increasing responsibility. He has been in the Medtech business since 1990, when he joined Johnson & Johnson as a sales rep. He left Johnson & Johnson in 2010 as Franchise Director Nordic & Baltics. Since then he has assisted smaller medtech companies in a consultancy capacity.

Mr. Laestadius holds a degree in Marketing and Business Administration from Gothenburg University.

---

Lene Lange


Lene Lange is professorship in Biotechnology, Aalborg University, Denmark.

In her research she seeks increased understanding of fungal biomass conversion in nature; and to hereby discover new fungal proteins of relevance upgrade of organic sidestreams and waste. All parts of the Fungal Kingdom are included in the discovery. Methods include fungal experimental molecular biotechnology, genomics, (meta)-transcriptomics and secretomics.

Lange has reached research director positions in both academia and industry; has hereby acquired experience from all parts of the knowledge-value-chain: research, technology, development, innovation, commercialization and policy making. She has a comprehensive portfolio of past and present positions in boards and advisory groups (including several chair and vice chair positions) for both public and private R&D organizations (global, European, Nordic, Danish).

---

Sybille Lenz

---

### Jan M. Lundberg



Jan M. Lundberg, Ph.D. is Executive Vice President for Science and Technology and President of Lilly Research Laboratories (LRL). He is also a member of the company's executive committee.

Dr. Lundberg joined Eli Lilly and Company January, 2010, with responsibility for Research and the Development Center of Excellence. Prior to assuming his position at Lilly, Dr. Lundberg served as Global Head of Discovery Research at AstraZeneca for ten years and was a member of the senior executive team. He was involved with numerous candidate drug nominations, development projects and support for marketed products.

---

### Ole Jørgen Marvik



Ole Jørgen Marvik, Sector Head, Health and Life Sciences, Innovation Norway. Marvik is the founder and former CEO of the antibody therapeutics company Affitech and has also been co-founder of several other biotech start-ups. He has been active in industry policy through many board and advisory positions, including the Norwegian Government's national biotech strategy. Recent projects focus on industry cluster development and national initiatives in areas such as medical biobanks, neuroscience, marine bio-prospecting and industrial biotechnology. Marvik is Norwegian representative in the OECD Task Force on Biotechnology. Marvik holds a PhD in molecular and structural biology and a master's degree in business management.

## SPEAKERS

---

Donnie McGrath

Donnie McGrath is Vice President, Business Development at Bristol-Myers Squibb. He has been working in academic medicine and the biopharmaceutical industry for 20 years. He heads a global team responsible for identifying, evaluating and transacting for all business development opportunities of interest to BMS.

He works with senior R&D and commercial leadership to design and execute the business development strategy for BMS.

He joined the Virology Global Clinical Research group of Bristol-Myers Squibb in 2005. He was the Reyataz® Development Lead until joining the Business Development group in 2010. Prior to joining BMS he was a physician in the infectious disease department at Tufts-New England Medical Center in Boston. He received his medical training in Dublin, Ireland, and in Boston, Massachusetts.

---

Sven Nelander

Sven Nelander is associate professor at the Dept of Immunology, Genetics and Pathology, Uppsala University. The Nelander lab focuses on systems biology of neural cancers, particularly GBM. The two focus areas of the lab are (i) new computational tools for cancer data mining, and (ii) developing patient-derived GBM stem cell cultures as a model for predictive oncology. SN has a study background in mathematics and medicine at Lund University (1995-2000), obtained his PhD at Gothenburg University (2001-2005), and conducted postdoctoral studies at Memorial Sloan Kettering Cancer Center (2006-2007). Since 2012 he is a strategic recruit to Uppsala University and Science for Life Laboratory.

---

### Catherine Taylor Nordgård



Catherine studied chemistry at Southampton University, before embarking on a PhD in the department of physiological sciences, Newcastle University on the topic of the mucus gel barrier and interactions with therapeutic biopolymers under the supervision of Prof. Adrian Allen and Prof. Jeff. P. Pearson.

She continued her research with Prof. Olav Smidsrød and Prof. Kurt I. Draget at the Norwegian University of Science and Technology in Trondheim, Norway, investigating the functional properties of biological soft materials and biological macromolecules, and pharmaceutical/biomedical applications related to these materials. This research has resulted in several patents, patent applications and out-licensed technologies.

---

### Gunilla Osswald



Extensive experience in drug development in neuroscience from pharmaceutical industry and biotech, with a track record of project delivery from preclinical to regulatory submission and launch.

Gunilla is CEO at BioArctic Neuroscience where she has been for 1.5 years. BioArctic Neuroscience is a biotech research company in Stockholm working on new effective treatments for patients with disorders in the CNS, focusing on Alzheimer's, Parkinson's disease and Spinal Cord Injuries.

Her previous role was VP Neurodegeneration at Astra Zeneca in Södertälje, where she has had several roles including Global Product Director, Head of Experimental Medicine, Head of Clinical Pharmacology, Head of Phase I Unit, Scientist. She also had the role as VP Södertälje Site Change and led the closure of AstraZeneca in Södertälje with 1300 affected people and transfer of 76 drug projects.

## SPEAKERS

---

Juni Palmgren

Professor of Biostatistics, Karolinska Institutet

Palmgren's research training is in mathematics, statistics and computer science, with focus on statistical epidemiology and statistical genetics. She is Professor of Biostatistics at Karolinska Institutet, Finland Distinguished Professor, FiDiPro, at the Institute for Molecular Medicine Finland, FIMM and holds the position as Secretary General for Research Infrastructures at the Swedish Research Council. She has been part of initiating the Swedish eScience Center, SeRC, (<http://www.e-science.se/>) and is PI of the SeRC flagship project e-Science for Cancer Prevention and Control, eCPC, at Karolinska Institutet.


---

Kirsi Vähä-Pietilä

Kirsi Vähä-Pietilä is a Finnish EUREKA project coordinator (NPC) promoting and activating international innovation cooperation between SMEs and representing Finland in EUREKA network. She has been actively involved in development of Eurostars joint programme and is responsible for Eurostars programme in Finland. Earlier she has been responsible for strengthening international cooperation in Tekes technology programs and providing services for collaboration. She has worked as an expert and a national contact point in EU framework programmes and as an adviser in Innovation Relay Center (IRC) Network. Before that she was a research scientist in fields of manufacturing and building technology at VTT Technical Research Centre of Finland.

---

### Dirk Pleimes



Managing Director and Chief Medical Officer.

Graduated in medicine and public health from Charité, Humboldt University, Berlin.

9 years of work experience in global medical affairs, clinical development, business development and strategic marketing in pharmaceutical companies based in Germany and the USA. Former Global Medical Lead Neurology, Ophthalmology (RVO) and Head of Global Medical Affairs Europe/ Canada Ophthalmology at Bayer Healthcare. Founder of SCINSPIRE Holding & Consulting and co-founder of Myelo Therapeutics GmbH leading R&D the program of oncology start-up.

---

### Dr. Jean-Francois Pouliot



Dr. Jean-Francois Pouliot is a physiologist and biochemist who obtained his degree from the University of Montreal.

Currently Director of Medical Affairs for Europe and Canada, he is responsible for medical and scientific engagements involving multiple countries.

After completing a post-doctoral training at McGill University where he worked on drug discoveries related to multidrug resistance reversing agents; Dr. Pouliot joined the pharmaceutical industry where he assumed several leadership roles in Clinical Research and Development.

Dr. Pouliot's researches lead to several publication and communication, mainly focused on optimization patient selection and schedule of drug administration. Throughout his career, he worked on numerous therapies that resulted in some major breakthroughs in cancer care including imatinib and immunotherapies.



## SPEAKERS

---

Niklas Prager

Niklas is currently CEO of Medivir and has a background from the pharmaceutical industry in the US and in Sweden.

He started his career with Merck in the US, and has also worked for their subsidiary MSD in Sweden, before he joined Pfizer and served as Country Manager for their Swedish business. Niklas has also served as CEO for Envirotainer, the world leader in leasing of containers for air freight of temperature sensitive goods, and Qbtech, the leading company in ADHD diagnostics and outcomes measurement. He has also served as chairman and director of the board in a number of listed and non listed companies, currently including CellaVision, Qbtech and eGain.

---

Volker Rindler

Co-Founder and Director Business Development at ALRISE Biosystems GmbH.

Volker studied mechanical engineering at the Aachen University of Technology and graduated in Bioprocess Engineering in 1995. He was awarded his doctor title from Helmholtz-Institute for Biomedical Engineering at the Aachen University of Technology in 2000. His doctoral research focused on the cryopreservation and lyophilization of cellular systems.

Volker has 14 years working experience in the field of drug delivery where he started in process development and manufacturing of drug-loaded micro particle formulations before he moved into non-technical management positions. As co-founder of ALRISE Biosystems he is a member of the management team and in charge of the company's business development.

---

### Sara Riggare



Sara Riggare is an engineer by training who decided that she wanted to combine her engineering skills with her patient experiences to try to improve the situation for herself and others with chronic diseases. She has studied health informatics at Karolinska Institutet and currently combines being a doctoral student at Karolinska with being an entrepreneur, in the role as “Chief Patient Officer” at Nerve Sweden AB. Sara’s work is dedicated to patient empowerment and digital selfcare tools for chronic conditions. She is a member of the BMJ patient partnership advisory group, ambassador to the World Parkinson Congress 2016, advisor to The Swedish Medical Products agency, and advisor to The Swedish Agency for Health and Care Services Analysis.

---

### Kim Sandell



Kim joined Pfizer in Strängnäs, Sweden, in 1999. He is currently holding a position as Operation Excellence & Operations Management lead at the site. Kim has held a range of positions at the site starting as a process engineer, moving into project lead and quality support to projects. He then resumed responsibility for the manufacturing at the site until he joined the project team for construction of a new biotech facility at the Strängnäs site. In the project Kim was responsible for starting up the new facility including tech transfer of two new process generations for the Drug Substance of Genotropin® and Somavert®.

Kim holds an MSc in chemical engineering from the Royal Institute of Technology, Sweden and an MBA from Reading University, Henley Business School, UK.

## SPEAKERS

---

Carina Schmidt

Carina Schmidt, CEO Athera Biotechnologies AB, MSc Chem Eng, has nearly 30 years industrial experience, mainly in business development and management, international marketing and product management within the life science area. During 15 years she has worked with Pharmacia Biotech/ Amersham Biosciences (now GE HealthCare). Later she founded Grasp Bioscience AB, where positions included management consultant, board director, interim CEO and business advisor to several biotech start-ups.

Delegate of the investment committee in ALMI Invest region Norr.

---

Christian K. Schneider

Christian K. Schneider, MD, is Medical Head of Division Medicines Licensing and Availability at the Danish Health and Medicines Authority.

At the European Medicines Agency (EMA), he is Alternate Member of the Committee for Medicinal Products for Human Use (CHMP) for Denmark, and Chair of the Biosimilar Medicinal Products Working Party (BMWP). Between 2009 and 2013, he was Chair of EMA's Committee for Advanced Therapies (CAT), and was co-opted member of the CHMP between 2007 and 2011 for the area of "Quality and safety (biological)", with expertise in Advanced Therapies - Gene, Cell and Tissue Therapies". Before 2011, he was Head of Division "EU Co-operation/Microbiology" at the Paul-Ehrlich-Institut, the German Federal Institute for Vaccines and Biomedicines.

---

### Ulrika Sehlstedt



Dr. Ulrica Sehlstedt is a Partner with Arthur D. Little, specialized in life science and healthcare. Her work includes strategy development, opportunity assessment, public procurement, operational & commercial due diligence, change management and program management, for both healthcare suppliers and providers. Before joining Arthur D. Little, Ulrica spent seven years as CEO for a molecular diagnostics start-up. She has also been a member of the Swedish Research Council's Scientific Council for Medicine for six years and a member of the 2007 national expert panel in Life Science Technologies for Future Research Leaders, a program launched by the Swedish Foundation for Strategic Research.

Ulrica holds a PhD in Biophysics from Stockholm University and a M.Sc. in Chemical Engineering from Chalmers.

---

### Jean De Serres



Jean De Serres is the CEO of Hema-Quebec, an organisation of 1350 employees serving the population of Quebec in blood products, tissues and stem cells.

Prior to that, he was VP Research, Regulatory & Business Development for Jubilant Life Sciences, HollisterStier and Draxis, a group of pharmaceutical companies where he developed a number of drugs in immunology, oncology and imaging as well as medical devices. He is also Founder and Board member of Med-Discovery, a Swiss biotech in oncology, as well as Biomilestones, a Canadian consulting company for biopharmas.

From 1999 to 2005, he has launched and been GM for CSL Behring Canada (previously Aventis Behring Canada). He has launched a number of private clinics, participated to created L'Omnipraticien, a medical newspaper and he has been President-Quebec and Board member of the Canadian College of Family Physicians from 1992 to 1996.

He has previously practiced medicine and directed teaching units at McGill University in Montreal. He has a MBA in life sciences and a M.Sc in public health.

## SPEAKERS

---

Christiane Smerling

Christiane Smerling has served as Head of Nuclear Medicine & Imaging at 3B Pharmaceuticals since January 2010.

She is responsible for 3BP's theranostic tracer development programs and manages the business development and partnering activities of 3BP's Nuclear Medicine division.

Prior to joining 3B Pharmaceuticals, Dr. Smerling has worked a scientist at Jerini AG, where she managed a discovery program identifying modulators of hypoxic signaling.

Dr. Smerling received her degree in biochemistry from the Freie Universität Berlin and her PhD from the University of Cambridge, where she studied the modulation of signal transduction and migration of fibrosarcoma cells by components of the extracellular matrix.

---

Tobias Sjöblom

Tobias Sjöblom is Associate Professor in tumor biology at Uppsala University, Uppsala, Sweden.

During his postdoctoral fellowship at the John Hopkins University, he performed the first exome-wide mutational analyses of breast and colorectal cancers.

He currently leads a research group in cancer genomics and is Program Director for U-CAN, a strategic cancer biobanking initiative supported by the Swedish government. Apart from structured sample collection, a major focus of U-CAN is the establishment of structured data sources in cancer care to support the needs of healthcare, industry and academia.

---

### Dr Claire Skentelbery



Claire Skentelbery has a BSc in agriculture from Aberdeen and a PhD in plant biochemistry from Lancaster.

Following her PhD, she moved into technical writing and scientific promotion within the Cambridge biotechnology cluster. Claire developed scientific network management through her work in Cambridge and scaled this up with the development and launch of the Council of European BioRegions (CEBR), a network of cluster managers across Europe which has the mission to defragment cluster development and SME support. She has been Network Manager of CEBR since 2003. In 2010, Claire also took on the role of Secretary General of the European Biotechnology Network, a cross sectoral network of scientists and all other actors involved in the development of the sector, which has the mission to facilitate partnerships. In her role as SG of EBN, Claire has developed and implemented activities in Brussels to deliver network mission and works with partners across the globe to build scientific and business partnerships.

---

### Leif Rune Skymoen



Leif Rune Skymoen has more than 10 years' experience from National, Scandinavian and European roles in the pharmaceutical industry.

When joining Nansen Neuroscience Network in 2013 he came from the role as head of Eli Lilly Norway. He has also served on the board of Norwegian Association for the Pharmaceutical Industry. Leif Rune holds a MSc degree in pharmacy from University of Oxford and University of Oslo and a Master of Management degree from BI Norwegian Business School.

## SPEAKERS

---

Christopher De Souza

Christopher de Souza, PhD, shares responsibility for the day-to-day operations of Broadview Ventures, including business development strategy, identification and screening of new investment opportunities, negotiation of partnering terms and deal structure, as well as portfolio company board involvement. He leverages 20 years of experience in biopharmaceutical R&D, business development and corporate strategy to help meet the Broadview Ventures mission.

Christopher started his pharmaceutical career at Novartis where he was a senior scientist in the Metabolic and Cardiovascular Diseases group and then Director of Strategic Alliances with responsibilities for the therapeutic area strategy, business development and alliance management. After Novartis, Christopher was VP of Business Development at SkyePharma US Inc, a drug delivery company, where he was responsible for out-licensing SkyePharma's clinical assets and drug delivery technologies. Christopher also founded a business development consulting practice with several clients including JSB-Partners, Diagnostics For All and Metaome.

---

Carl-Johan Spak

Carl-Johan Spak is Executive Vice President, Development & Technology in Recipharm AB and CEO of Recipharm Venture Fund AB.

He has been with Recipharm AB since 2009. Prior to this he was the head of the Nordic Region for Meda AB and in several positions at Recip AB since 1995. He has a PhD in pharmacology and cardiology from Karolinska Institutet.

He has positions in the boards of Cobra Biologics, Prokarium Ltd, Symcel, Cormorant Pharmaceuticals, Empros Pharma and KAHN Medical.

---

### Regina Summer



SNITTS is the Swedish network for Innovation and Technology Transfer Support.

We represent individuals and organizations that work with knowledge exchange and the broader utilization of research. Our purpose is to strengthen our members through monitoring the outer world, creating awareness and professional development.

As the Director of SNITTS I am responsible for the business and service development of the organization. My main focus areas are to establish professional development programs for our members, to expand the professional network, create awareness of the profession and initiate valuable partnership for the organization. I am also project leader for the Nordic Tech Transfer network for the health sector, which SNITTS has been appointed by the Nordic Council of ministers, to coordinate. The project consists of members from Iceland, Norway, Denmark, Finland and Sweden.

---

### Eirik Sundby



“Eirik Sundby from Sandefjord (Norway) finalized the Ph. D study in 2003 dealing with enzymatic reductions and kinetic resolutions at the University of Natural Sciences and Technology (NTNU) with Professor Thorleif Anthonsen. After graduation he got a position at HiST as Associate Professor. His research interests extend are mainly (bio)synthesis of xenobiotic metabolites and asymmetric and regioselective synthesis. The latest years he has switched towards the synthesis and optimization of bioactive compounds of different origin focusing especially on kinase inhibitors.”



## SPEAKERS

---

Frank Swenson

Dr. Swenson is currently a consultant, in San Francisco, California. At Pfizer he was Director, Precision Medicine Diagnostics and the research and commercial lead for Pfizer's AD Diagnostic program. He led multiple Precision/Personalized Medicine programs exploring and validating clinical assays as well as ophthalmic, and imaging biomarkers in Neurosciences and Infectious diseases. For 6 years he initiated several collaborative pilot R&D studies to detect and monitor novel Early AD biomarkers. Prior to Pfizer, he worked for over 20 years at several start-up and large US Diagnostics companies in Research and Business development roles. He has developed several worldwide regulatory approved medical devices/diagnostics.

Dr. Swenson has a Ph.D. in Medical Sciences, MS in Immunology and a Doctorate in Optometry.

---

Benjamin Thiering

Benjamin Thiering joined the Health Care Industries Unit at Berlin Partner for Business and Technology, the economic development agency for Berlin, in 2013.

He holds a degree in economic geography from Humboldt-Universität zu Berlin and started his life science career with his thesis in the Business Development of Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig. After his previous affiliation with the German state of Hesse and the Cluster for Industrial Biotechnology (CIB) in Frankfurt, Benjamin is now responsible for supporting Biotech & Pharma companies in their relocation and startup ventures in the German Capital region within the Cluster HealthCapital.

---

### Corinne Venot



Corinne Venot, holds a PhD in Molecular Biology and a Master in pharma marketing from ESCP-EAP Paris.

She has always been focused in the field of Oncology, taking various positions from marketing, early drug discovery to scientific Business Development.

Since 2008, within Sanofi Oncology Division, she is specialized in preclinical/discovery assets with an emphasis on oncobiologics including antibody drug conjugates.

As Director of oncology business opportunities, her main responsibilities are portfolio gap analysis, scouting, evaluation, negotiation and deal making.

She has been playing a major role in building the following licenses and partnerships: in-licensing p53/mdm2, small molecule inhibitor from Ascenta/Univ of Michigan; Dana Farber/Belfer Institute, strategic research collaboration; in licensing of antibody products for ADCs from Oxford Biotherapeutics.

---

### Loic Vincent



Oncology Scientist with 15 years of international biotech/pharma industry experience. Pharmacologist by initial training, with a PhD from the University of Rouen, France, and post-doctoral studies in Oncology at Weill Medical College of Cornell University, New-York, NY, USA.

I have held a various industry positions in scientific, managerial and now licensing departments. I joined Sanofi Oncology in August 2007 as Head of Pharmacology until 2013, and I am currently responsible for the identification, the scientific/medical evaluation & in-licensing of oncology opportunities in Immunotherapy, and I am the chair of the Immunotherapy Strategy & Expertise Team at Sanofi Oncology.

I'm author and co-author of 31 scientific papers and 37 poster/oral presentations.

---

### Jan Wifstrand



Jan Wifstrand is the founder and CEO of Rapidus, [www.rapidus.se](http://www.rapidus.se), which is a digital newswire that covers the lifescience-industry, IT and related issues in the Öresund Region Malmö-Copenhagen. Before establishing Rapidus, Wifstrand was the Editor of Dagens Nyheter, the leading Swedish quality newspaper and, prior to that, Editor of Sydsvenskan, another major Swedish daily. He is nowadays one of the most sought-after moderators in Sweden, especially in the fields of business, politics and sports.

---

### Ketil Widerberg



Ketil F. Widerberg, MBA, is General Manager of Oslo Cancer Cluster. He builds on a long experience in realizing new projects within oncology in the biopharmaceutical company Photocure ASA in collaboration with academic institutions and international commercial partners.

Ketil has a broad operational experience ranging from explorative project management to being responsible for business development.

Widerberg's educational background spans from preclinical medical school to management studies. He also holds a MBA from the University of Cambridge.

---

## Bengt Winblad



Professor Bengt Winblad, MD, PhD has been involved in the field of dementia research for many years. After pre-clinical medical studies in Vienna, Austria, he became MD 1971 and took his PhD in 1975 at Umeå University, Sweden, where he also became Docent in 1977 and Professor of Geriatric Medicine and Chief Physician in 1982. Since 1987, he is working in Stockholm, Sweden as Professor of Geriatric Medicine at the Karolinska Institutet and is Chief Physician at Karolinska University in Huddinge. Professor Winblad is Director of the Alzheimer Research Center at Karolinska Institutet, as well as the Swedish Brain Power research network.

He is co-chairing the European Alzheimer Disease Consortium (EADC) and is the Coordinator of the European Union Joint Program on Neurodegenerative Disorders (EU-JPND) project on biomarkers in Alzheimer and Parkinson diagnostics, BIOMARKAPD. He chaired the Medical Scientific Advisory Panel of the Alzheimer Disease International (ADI) 2007-2013.

Bengt Winblad has been guest professor at the Department of Psychiatry in Frankfurt and appointed honorary professor at Beijing University, Wuhan University and Shanghai University in China.

---

## Ola Winqvist

Dr. Ola Winqvist is a Professor of Cellular Immunotherapy, Head of Translational Immunology, and Senior Consultant in Clinical Immunology at the Karolinska Institutet and Karolinska University Hospital. The Swedish Research Council and the Swedish Cancer Society have continuously supported Ola's research since 1999, and he has received various competitive grants from the European Union and Swedish Governmental Agency for Innovation Systems for the development of immunological therapeutics. Ola has an M.D and Ph.D. from Uppsala University in Sweden, and did his postdoctoral research at the Scripps Research Institute in the United States.

## PROGRAM

SUNDAY 7 SEPTEMBER 2014			
Time		Level	Location
15:00 – 18:00	EXHIBITOR'S SETUP	Level 4	Networking Hall
15:00 – 19:00	PRE-REGISTRATION	Level 4	Main Entrance Hall
19:00 – 20:30	WELCOME RECEPTION	Level 4	Networking Hall
MONDAY 8 SEPTEMBER 2014			
Time		Level	Location
07:30 – 09:00	WELCOME BREAKFAST	Level 4	Networking Hall
07:30 – 18:30	EXHIBITION OPEN	Level 4	Networking Hall
09:00 – 10:30	WELCOME & OPENING SESSION The Nordic Region, a region at the forefront of global development in Life Sciences & Healthcare Session hosted by Sweden Bio Welcome address Dr. Jonas Ekstrand – CEO, SwedenBIO Moderator Mr. Jan Wifstrand – CEO and founder, Rapidus Speakers Dr. Jan M Lundberg – Executive Vice President, Science and Technology, and President, Lilly Dr. Lene Lange – Director of Research, Professor in Biotechnology and Campus Director for Aalborg University Copenhagen Dr. Charlotte Brogren – General Director, Vinnova Dr. Ulrika Sehlstedt – Principal, Healthcare, Arthur D. Little	Level 2	Room C1/C2/C3
10:30 – 11:00	BREAK	Level 4	Networking Hall
11:00 – 12:30	INTERNATIONAL INVESTORS SESSION Session hosted by Business Sweden, HealthCap and Industrifonden Moderator Dr. Nina Rawal – Investment Manager Life Science, Industrifonden INVESTORS PITCHING IN A ROW – WHO WE ARE AND WHAT WE WANT! Mr. David Phillips – VP & Partner, SR One – GSK Dr. Viktor Drvota – Head of investment Ares Life Science, SEB Venture Capital Mr. Per Aniansson – Investment Director, Fourierttransform Mr. Claes Pos – Investment Manager, Almi Invest Dr. Marten Steen – Partner, HealthCap Mr. Carl-Johan Spak – Executive VP, Development & Technology, Recipharm Venture Fund Mr. Eric de la Fortelle – Venture Partner, Seventure Partners Dr. Bobby G. Son – Investment Director, Novo Seeds Mr. Claus Asbjørn Andersson – Partner, Sunstone Capital Mr. Jasper Bos – Director, Merck Serono Ventures Mr. Christopher de Souza – Director, Broadview Ventures Ms. Hedvig Andersen – Investment Manager, Industrifonden ROUND TABLE – VENTURE CAPITAL AND PRIVATE EQUITY, WHAT'S UP? Speakers Mr. Adam Kostyál – Senior Vice President, Nasdaq CCG EMEA Mr. David Phillips – VP & Partner, SR One – GSK Dr. Björn Odlander – Partner, HealthCap Mr. Seppo Mäkinen – Senior Advisor, Merieux Développement	Level 2	Room C1/C2/C3

The Swedish Life Science Industry Organisation  
**swedenBIO**



**HealthCap**

**Industrifonden**

12:30 – 13:30	LUNCH	Level 4	Networking Hall
13:30 – 18:30	FACE-TO-FACE MEETINGS	Level 3	Business Forum
13:30 – 18:00	COMPANY & PITCHING PODIUM PRESENTATIONS	Level 2	Room 26
	13:30 Bergen Teknologioverføring AS		
	13:37 Dilaforette AB		
	3:45 Lipopharma Therapeutics SL		
	13:52 Medicortex Finland Oy		
	14:00 Nextera AS		
	14:07 NMI Reutlingen		
	14:15 CALIXAR SAS		
	14:22 CiToxLAB Scantox		
	14:30 Diamyd Medical		
	14:37 Targovax AS		
	14:45 Cobra Biologics		
	14:52 FOI - Swedish Defence Research Agency		
	15:00 Gaea		
	15:07 Genlabet Biopharmaceuticals		
	15:15 SIRION Biotech GmbH		
	15:22 SOLVE Research and Consultancy AB		
	15:30 SYNCROSOME		
	15:37 UNITHER PHARMACEUTICALS		
	15:45 Admescope		
	16:00 Pharmatory		
	16:15 INVENTIVA		
	16:30 Medicyte GmbH		
	16:45 PledPharma AB		
	17:00 Cambrex Corporation		
	17:15 Axiogenesis		
	17:30 Herantis Pharma Plc		
	17:45 Medipan		
14:00 – 18:00	PHARMA & COMPANY PRESENTATIONS	Level 2	Room 27
	14:00 AbbVie		
	14:20 BMS		
	14:40 J&J		
	15:00 Sanofi		
	15:20 MSD		
	15:40 Pfizer		
	16:00 Lilly		
	16:20 Recipharm		
	16:40 Grunenthal		
	17:00 Greater Helsinki Promotion		
	17:07 Turku Science Park		
	17:15 Acreo Swedish ICT		
	17:22 SuperECG		
	17:30 Invest in Toulouse		
	17:37 Projektsupport S-O AB		
	17:45 Scandinavian Biopharma		

## PROGRAM

14:00 – 15:30	<b>THE NEW INNOVATION ECOSYSTEM</b>  <b>HOW TO SUPPORT ENTREPRENEURSHIP AND GROWTH</b> <p>Research &amp; Development within healthcare is a constantly evolving landscape of emerging science and technologies, with the demands on innovation and entrepreneurs changing day by day, whether for regulatory, financial or clinical reasons. This panel brings together the innovation faces of life science companies, policy makers and market specialists to identify how the pressures and triggers for young industry have changed and are changing. The panel also addresses what can and should be done to support the commercialisation of innovation in such a challenging global environment.</p> <p>Session hosted by European Biopharmaceutical Enterprises, European Biotechnology Network, Swiss EUREKA Chairmanship and the Swiss-Swedish Innovation Initiative SWII.</p> <p><b>Moderators</b>  Ms. Titta Rosvall-Puplett – Executive Director, European Biopharmaceutical Enterprises (EBE)  Dr. Claire Skentelbery – Secretary General at European Biotechnology Network (EBN)</p> <p><b>Speakers</b>  Dr. Magnus Björnsne – Executive Director, AZ Innovation Centre  Dr. Kurt Hertogs – Head Platform Innovation &amp; Incubator Strategy for Johnson &amp; Johnson Innovation  Mr. Ole Jørgen Marvik – Sector Head, Health and Life Sciences, Innovation Norway  Mr. Florin Müller – Deputy Head of Innovation, State Secretariat of Education, Research and Innovation – (SERI)  Dr. Patric Källmam – Senior Partner and Strategic Advisor, Healthcare Market, Vasco Advisors</p>	Level 2	Room C1/C2
	    		
14:00 – 15:30	<b>CHRONIC DISEASES - FOCUS ON CARDIOVASCULAR AND AUTOIMMUNE DISEASES</b>  <p>Chronic diseases are a challenge for the society and likewise an opportunity for the life science industry. By 2030, it is estimated that 7 of every 10 deaths worldwide will be the result of a chronic disease with CVD being the largest contributor. Immune-mediated diseases a poorly understood category of diseases, possessing a significant public health burden. Recent progress in academic research and the industry's implementation of translational processes has paved the way for novel approaches. With selected examples from cardiovascular- and inflammatory autoimmune diseases.</p> <p>In addition, m-health services can be an efficient part of therapies for most chronic diseases in order to achieve improved outcome and safety. Although promising results of m-health initiatives, very few are used today in ordinary healthcare. Combining medicines, treatment plans, and patient self-management support into one product offering has the potential to improve chronic diseases therapies in several ways. This session will highlight and discuss what is driving innovation towards novel effective and safe treatments.</p> <p><b>THE FUTURE OF THERAPIES IN CARDIOVASCULAR DISEASE</b>  <b>Moderator</b>  Dr. Anders Ekblom – MD, Board Member, SwedenBIO</p> <p><b>Speakers</b>  Ms. Elisabeth Björk – VP CVMD Global Medicines Development and Site Lead AZ Mölndal, R&amp;D, AstraZeneca  Mr. Jan Fjellström – Partner, ScientificMed  Ms. Carina Schmith – CEO, Athera Biotechnologies</p> <p><b>DRIVING INNOVATION IN INFLAMMATORY AUTOIMMUNE DISEASES</b>  <b>Speakers</b>  Dr. Anand Gautam – Director, Innovation Sourcing, Novo Nordisk  Dr. Ola Winqvist – Professor, Karolinska University Hospital and CSO Immune Therapy Holding  Dr. Jean de Serres – CEO, Héma-Québec</p>	Level 2	Room C3

15:30 – 16:00	BREAK	Level 4	Networking Hall
16:00 – 17:30	<p><b>ECCP - EARLY STAGE ONCOLOGY OPPORTUNITIES</b></p> <p>Teaming-up for the success stories of tomorrow. Session hosted by Oslo Cancer Cluster and Cancer Bio-Santé, supported by BioWin and Invest in Skåne</p> <p><b>Moderator</b> Mr. Ketil Widerberg – Managing Director, Oslo Cancer Cluster</p> <p><b>Speaker</b> Dr. Corinne Venot – Sanofi Oncology Division, Oncology Business Opportunity</p> <p><b>NORTH ACADEMIC INNOVATION SHOWCASE: PRE-COMMERCIAL ONCOLOGY PROJECTS FROM NORDIC TTOS AND INCUBATORS ARE PRESENTED IN SHORT PITCHES</b></p> <p><b>Speakers</b> Dr. Vincenzo Cerullo – University of Helsinki, Finland: PeptiCrad Dr. Cathrine Taylor – Nordgård, NTNU, Norway: RIXOVA Dr. Eirik Sundby – NTNU, Norway: Kinase inhibitors Dr. Mohammed Amarzguioui – Inven2 / for Oslo University Hospital, Norway: Tankyrase inhibitor Dr. Mohammed Amarzguioui – Inven2 / for Oslo University Hospital, Norway: Cologuide Prognostic Test Dr. Thomas Helleday – Scilifelab / Karolinska Institutet, Sweden: MTH1 Inhibitor Dr. Ann Zahle Andersen – University of Southern Denmark, Denmark: KRAS targeting SSOs</p> <p><b>EARLY PHASE INNOVATION FROM HEALTH CAPITAL BERLIN-BRANDENBURG</b></p> <p><b>Speakers</b> Dr. Christiane Smerling – Head of Nuclear Medicine &amp; Imaging, 3B-Pharma GmbH Mr. Dirk Pleimes – Managing Director and Chief Medical Officer, MyeloTherapeutics GmbH Dr. Volker Rindler – Director Business Development, Alrise Biosystems GmbH</p> <p><b>Speaker</b> Dr. Maria Bobadilla – Senior Director, Academic Innovation Partnering, Hoffmann-La Roche</p>	Level 2	Room C1/C2



Cancer-Bio-Santé  
CLUSTER

**BioWin**  
THE HEALTH CLUSTER OF WALLONIA

**invest in skåne**  
part of business region skåne





## PROGRAM



16:00 – 17:30	<p><b>NORDIC-SWISS INNOVATION PARTNERSHIPS</b></p> <p>This session is dedicated to best practice in innovation partnerships between innovative companies from world-leading innovation regions Switzerland and the Nordics. Presentations about collaboration potential, information about suitable funding opportunities and companies' best practice examples of Swiss-Nordic collaborations as well as extensive Q&amp;A possibilities will provide ample guidance for how to set up a successful innovation project.</p> <p>Session hosted by the Swiss EUREKA Chairmanship and the Swiss-Swedish Innovation Initiative SWII</p> <p>Moderator Mr. Stefan Klausner – Project Manager, Federal Department of Economic Affairs, Education and Research (EAER), State Secretariat for Education, Research and Innovation (SERI), Innovation Unit</p> <p>SETTING-UP A NORDIC-SWISS INNOVATION PARTNERSHIP</p> <p>Speakers</p> <p>How to set up a EUREKA/Eurostars project Mr. Gunnar Sandberg – Programme Manager Health Division, Vinnova and Project Officer Eureka/Eurostars Projects Life Science</p> <p>Eurostars and EUREKA funding in Finland Ms. Kirsi Vähä-Pietilä – National EUREKA Project Coordinator, Finnish EUREKA Office at Tekes – the Finnish Funding Agency for Innovation</p> <p>Stockholm Business Region Life Science Hot List Ms. Ylva Hultman – Business Development Manager, Stockholm Business Region Development</p> <p>Biotech in Switzerland Ms. Cathy Kroll – COO, Swiss Biotech Association</p> <p>Best-practice examples of Swiss-Scandinavian Biotech partnerships Dr. Björn Walse – CEO, SARomics Biostructures, Saromics &amp; Insili research alliance Dr. Matthias Peterhans – CEO, CASCination, Eurostar project CAMILIS</p> <p>QUESTIONS &amp; ANSWERS</p>	Level 2	Room C3
19:00 – 22:00	<p><b>OFFICIAL NETWORKING RECEPTION</b></p> <p>Reception hosted by Stockholm City and Stockholms Stad</p> <p>Stockholm City Hall – Hantverkargatan 1, 111 52 Stockholm 5 min walking distance from the Waterfront Congress Center</p>		Stockholm City Hall









TUESDAY 9 SEPTEMBER 2014		
Time	Level	Location
07:30 – 09:00	WELCOME BREAKFAST	Level 4 Networking Hall
07:30 – 18:00	EXHIBITION OPEN	Level 4 Networking Hall
08:00 – 17:00	FACE-TO-FACE MEETINGS	Level 3 Business Forum
08:30 – 12:30	COMPANY AND PITCHING PODIUM PRESENTATIONS	Level 2 Room 26
	08:30 Neurotar Ltd	
	08:45 Pre Diagnostics AS	
	09:00 Vicore Pharma AB	
	09:15 XSpray Microparticles AB	
	09:30 APIM Therapeutics AS	
	09:45 Cormorant Pharmaceuticals	
	10:00 Lytix Biopharma AS	
	10:15 Oncos Therapeutics Ltd.	
	10:30 Vaccibody AS 10:45 CR Competence AB	
	11:00 DeSiTech Ltd	
	11:15 Integrated DNA Technologies	
	11:30 OssDesign AB	
	11:45 Link Medical	
	12:00 Oncovet	
	12:15 Pelago Bioscience AB	
09:00 – 10:30	ECCP - CANCER IMMUNOTHERAPIES	Level 2 Room C1/C2
	Session hosted by Oslo Cancer Cluster and Cancer Bio-Santé, supported by BioWin and Invest in Skåne	
	Moderator	
	Dr. Johan Christenson – MD, Partner, HealthCap	
	NOVEL OPPORTUNITIES VIA DISRUPTIVE INNOVATION	
	Speakers	
	Mr. Donnie McGrath – Vice President Search & Evaluation, Business Development, Bristol-Myers Squibb	
	Dr. Loic Vincent – Sanofi Oncology Division, Oncology Business Opportunity	
	SPOTLIGHT: INNOVATION ECOSYSTEMS IN IMMUNO-ONCOLOGY – AN OVERVIEW OF ACADEMIC CENTRES, SPIN-OFFS AND EMERGING PIPELINES IN EUROPEAN CLUSTERS	
	Speakers	
	Medicon Valley, Sweden/Denmark	
	Dr. Sibylle Lenz – CEO, Alligator Bioscience	
	Oslo Cancer Cluster, Norway	
	Mr. Øyvind Arnesen – CEO, Ultimovacs AS	
	Cancer-Bio-Santé, Toulouse, France	
	Dr. Jean-Jacques Fournié – Professor and Director Cancer Research Center of Toulouse	
	Cancer Campus / Medicien, Paris, France	
	Mr. Erwan Corcuff – CEO, Axenis	
	BioWin, Wallonia, Belgium	
	Mr. Fouad Eddahri – Scientific Liaison Officer, ImmuneHealth	
	REGULATORY PERSPECTIVE	
	Speaker	
	Dr. Bertil Jonsson – MD, Vice-Chair, CHMP Efficacy Working Party – Human Medicines & Swedish Medical Products Agency	



## PROGRAM

09:00 – 10:30	<b>MEDICAL NEEDS AND RECENT TRENDS IN NEUROSCIENCE</b>  Central nervous system disorders present substantial unmet medical needs and are predicted to grow exponentially in the coming decades due to the increase in average life span throughout the population. This session will highlight new trends and developments helping to translate research in neuroscience into novel therapies for such disorders. Session hosted by Nansen Neuroscience Network and GE  <b>Moderator</b> Mr. Leif Rune Skymoene – CEO, Nansen Neuroscience Network, Norway  <b>Speakers</b> Extended focus for target oriented research in Alzheimer disease. Dr. Bengt Winblad – Professor, Karolinska Institute Finding drugs for Alzheimer's disease – why is it so difficult? Dr. Eric Karran – Director of Research, Alzheimer's Research UK Identifying early stage AD patients in drug trials using biomarkers /diagnostics is crucial. Dr. Frank Swenson – CSO & BD, Pre Diagnostics AS A novel approach to drug development in Alzheimer's disease Dr. Gunilla Osswald – CEO, BioArctic Neuroscience AB	Level 2	Room C3
	  		
09:00 – 12:30	<b>PHARMA AND COMPANY PRESENTATIONS</b>  08:30 Promega Biotech AB 08:45 TFS 09:00 Aseptic Technologies SA 09:15 Bone Index Finland Ltd. 09:30 EBS Technologies GmbH 09:45 Debiopharm International S.A. 10:00 Avalon Health Economics 10:15 Genohm 10:30 Photo Dynamic Therapy LLC 10:45 SGS 11:00 AstraZeneca 11:20 Novo Nordisk 12:00 Roche	Level 2	Room 27
10:30 – 11:00	<b>BREAK</b>	Level 4	Networking Hall

11:00 – 12:30	<p><b>ECCP - BIOMARKERS, BIOBANKS AND BIG DATA IN ONCOLOGY</b></p> <p>How to accelerate product development and improve patient treatment. Session hosted by Oslo Cancer Cluster and Toulouse Cancer Bio-Santé, supported by BioWin and Invest in Skåne</p> <p><b>Moderator</b> Dr. Carl Borrebaeck – Director CREATE Health, Professor Lund University</p> <p><b>ADVANCING INFRASTRUCTURES TO EXPLOIT BIOBANKS ASSETS</b></p> <p><b>Speakers</b> Predictive oncology: systems-scale analysis and prospective modeling of cancer stem cells from patients Dr. Sven Nelander – Department of Immunology, Genetics and Pathology, Cancer and Vascular Biology, Uppsala University</p> <p>Individualized risk prediction and novel screening tools Dr. Juni Palmgren – Professor, Karolinska Institutet, Steering Group member at The Swedish e-Science Research Centre (SeRC)</p> <p>The power of population based cohort studies and biobanks in biomarker research Dr. Christian Jonasson – CSO, Lifandis AS</p> <p>U-CAN: cancer biobanking for biomarker discovery Dr. Tobias Sjöblom – Associate Professor, Uppsala University, Program Director, U-CAN Project</p> <p><b>INDUSTRY CASES</b></p> <p><b>Speakers</b> From the quest for the perfect drug to optimal patient selection Mr. Jean-Pol Detiffe – CEO, OncoDNA</p> <p>OncoDEEP: tumor molecular profiling to help drug prescription and clinical trials selection Dr. Jean-Francois Pouliot – European Medical Lead Oncology, MSD</p> <p><b>Panel Discussion</b> Introduction by Ms. Maria Fagerkvist – Vice Director, The Swedish Trade Association for the Research-Based Pharmaceutical Industry (LIF)</p>	Level 2	Room C1/C2
		    	
11:00 – 12:30	<p><b>REDEFINING EARLY STAGE INVESTMENTS</b></p> <p>The fundraising landscape for early stage biotech and medtech companies has changed globally: Venture capital has become scarce and left a void that is being filled by a plethora of new entities including patient groups, venture philanthropy, family offices, virtual pharma, and corporate venture groups. This panel brings together representatives from new investor categories and seeks to define who they are, what opportunities they are seeking, and how early stage life science entrepreneurs should approach them to initiate a dialogue based on fit.</p> <p>Session hosted by Life Science Nation</p> <p><b>Moderator</b> Dennis Ford – Founder &amp; CEO, Life Science Nation, USA</p> <p><b>Speakers</b> Dr. Karin Aase – National Contact Point for Small and Medium Sized Enterprises (SME) and Access to Risk Finance International Collaboration and Networks Division, VINNOVA – Swedish Governmental Agency for Innovation Systems Mr. Peter Braun – Board Member EBAN, Switzerland Dr. Christopher de Souza – Broadview Ventures Inc, USA Dr. Marc Van de Craen – Managing Director, BiotechSubsidy, Belgium Ms. Saharla Ahmed – Msc Business Analyst Wellcome Trust</p>	Level 2	Room C3
			

## PROGRAM

12:30 – 13:30	LUNCH	Level 4	Networking Hall
14:00 – 15:30	<p><b>NORDIC LANDSCAPE &amp; NORDIC STARS AWARDS</b></p> <p>EY presents its new report The Nordic Life Science sector and the winners of the Nordic Stars Awards will be announced. Session hosted by Innomedica and EY</p> <p><b>Moderator</b> Ms. Tanja Dowe – Managing Partner, Innomedica Ltd</p> <p><b>INTRODUCTION TO THE NORDIC LIFE SCIENCE LANDSCAPE</b></p> <p><b>Speakers</b> Mr. Jan-Olof Jacke – VP Finance, Global Products &amp; Portfolio Strategy and R&amp;D, AstraZeneca and President, AstraZeneca AB Ms. Ylva Berg – President and CEO, Business Sweden – The Swedish Trade &amp; Invest Council Mr. Kim Sandell – Director Business and Supply and Mr. Jesper Eriksson – Operational Excellence, Black belt 60, Pfizer</p> <p><b>NORDIC LIFE SCIENCE SECTOR STUDY 2014</b></p> <p><b>Speakers</b> Mr. Frederic Lacuppinad – Managing General and Partner, Directure Mr. Jan-Olof Jacke – VP Finance, Global Products &amp; Portfolio Strategy and R&amp;D, AstraZeneca and President, AstraZeneca AB Mr. Kim Sandell – Director Business and Supply and Mr. Staffan Folin – Partner, Nordic Life Sciences Sector Leader, EY Mr. Staffan Folin – Partner, Nordic Life Sciences Sector Leader, EY</p> <p><b>NORDIC STARS AWARD</b> Announcement of winners of the Nordic Stars Award 2014</p>	Level 2	Room C1/C2/C3
15:30 – 16:00	BREAK	Level 4	Networking Hall
16:00 – 17:00	<p><b>CLOSING PLENARY – WHAT NEEDS TO BE IMPROVED IN THE INNOVATION ECO SYSTEM AND HOW WILL I CONTRIBUTE?</b></p> <p>Representatives from the Life Science Sector will discuss tomorrow's Life Science landscape. Session hosted by Arthur D. Little</p> <p><b>Moderator</b> Mr. Nils Bohlin – Managing Partner Global Health Industries Practice, Arthur D. Little</p> <p><b>Speakers</b> Mr. Niklas Prager – President and CEO, Medivir AB Dr. Christian K. Schneider – Medical Head of Division, Medicines Licensing and Availability, Danish Health and Medicines Authority Mr. Petrus Laestadius, Vice President, Swedish Medtech Ms. Sara Riggare – Doctoral Student, Karolinska Institutet, Founder &amp; Chief Patient Officer, Nerve Labs</p>	Level 2	Room C1/C2/C3
17:00 – 18:00	CLOSING RECEPTION	Level 4	Networking Hall



**Arthur D Little**

## 8 SEPTEMBER C1 – C2 -LEVEL 2

Date	Time	Company	Presenter Name	Presentation	Specialty	Location
8 september	11.00	Almi Invest	Claes Post	3 min	Investor	C1-C2 Level 2
8 september	11.00	Broadview Ventures	Christopher De Souza	3 min	Investor	C1-C2 Level 2
8 september	11.00	Fouriertransform	Per Aniansson	3 min	Investor	C1-C2 Level 2
8 september	11.00	Healthcap	Marten Steen	3 min	Investor	C1-C2 Level 2
8 september	11.00	Industrifonden	Hedvig Andersen	3 min	Investor	C1-C2 Level 2
8 september	11.00	MS Ventures	Jasper Bos	3 min	Investor	C1-C2 Level 2
8 september	11.00	Novo Seeds	Bobby G. Soni	3 min	Investor	C1-C2 Level 2
8 september	11.00	Recipharm Venture Fund	Carl-Johan Spak	3 min	Investor	C1-C2 Level 2
8 september	11.00	Seb Venture Capital	Viktor Drvota	3 min	Investor	C1-C2 Level 2
8 september	11.00	Seventure Partners	Eric De La Fortelle	3 min	Investor	C1-C2 Level 2
8 september	11.00	SR-One GSK Venture Fund	David Phillips	3 min	Investor	C1-C2 Level 2
8 september	11.00	Sunstone Capital	Claus Asbjørn Andersson	3 min	Investor	C1-C2 Level 2
8 september	11.00	The Wellcome Trust	Saharla Ahmed	3 min	Investor	C1-C2 Level 2

## 8 SEPTEMBER ROOM 26 -LEVEL 2

Date	Time	Company	Presenter Name	Presentation	Specialty	Location
8 september	13.30	Bergen Teknologioverføring	Torsten Porwol	5 min	Academic Early Stage	26 - Level 2
8 september	13.37	Dilaforette	Christina Herder	5 min	Academic Early Stage	26 - Level 2
8 september	13.45	Lipopharma Therapeutics	Vicenc Tur Tur	5 min	Academic Early Stage	26 - Level 2
8 september	13.52	Medicortex Finland	Adrian Harel	5 min	Academic Early Stage	26 - Level 2
8 september	14.00	Nextera	Thomas Andersen	5 min	Academic Early Stage	26 - Level 2
8 september	14.07	NMI Reutlingen	Christian Schmees	5 min	Academic Early Stage	26 - Level 2
8 september	14.15	Calixar	Anass Jawhari	5 min	Drug Development	26 - Level 2
8 september	14.22	Citoxlab Scantox	Peter Glerup	5 min	Drug Development	26 - Level 2
8 september	14.30	Diamyd Medical	Peter Zerhouni	5 min	Drug Development	26 - Level 2
8 september	14.37	Targovax	Hanne Mette Kristensen	5 min	Drug Development Oncology	26 - Level 2
8 september	14.45	Cobra Biologics	Magnus Gustafsson	5 min	CRO	26 - Level 2
8 september	14.52	Foi - Swedish Defence Research Agency	Emelie Näslund Salomonsson	5 min	CRO	26 - Level 2
8 september	15.00	Gaea	Nigel Goodman	5 min	CRO	26 - Level 2

## PRESENTERS – WHERE AND WHEN

8 september	15.07	Genibet Biopharmaceuticals	Tiago Ferreira	5 min	CRO	26 - Level 2
8 september	15.15	Siron Biotech	Kathrin Schmitt	5 min	CRO	26 - Level 2
8 september	15.22	Solve Research And Consultancy	Matilda Ulmius Storm	5 min	CRO	26 - Level 2
8 september	15.30	Syncosome	Arnaud Peyronnier	5 min	CRO	26 - Level 2
8 september	15.37	Unither Pharmaceuticals	Christine Adam	5 min	CRO	26 - Level 2
8 september	15.45	Admescope	Minna Komu	12 min	CRO	26 - Level 2
8 september	16.00	Pharmatory	Jaana Karjalainen	12 min	CRO	26 - Level 2
8 september	16.15	Inventiva	Jerome Bernard	12 min	CRO	26 - Level 2
8 september	16.30	Medicyte	Björn Lindemann	12 min	Academic Early Stage	26 - Level 2
8 september	16.45	Pledpharma	Jacques Näsström	12 min	Academic Early Stage	26 - Level 2
8 september	17.00	Cambrex	Alexandra Pichard Nielsen	12 min	Drug Development	26 - Level 2
8 september	17.15	Axiogenesis	Tristan Pritchard-Meaker	12 min	Drug Development	26 - Level 2
8 september	17.30	Herantis Pharma	Pekka Simula	12 min	Drug Development	26 - Level 2
8 september	17.45	Medipan	Linda Hallen	12 min	Drug Development	26 - Level 2

### 8 SEPTEMBER ROOM 27 -LEVEL 2

Date	Time	Company	Presenter Name	Presentation	Specialty	Location
8 september	15.00	Sanofi	Heike-Andrea Wieland	20 min	Pharma	27 - Level 2
8 september	15.20	MSD	Ulf Janzon	20 min	Pharma	27 - Level 2
8 september	15.40	Pfizer	Maria Flocco	20 min	Pharma	27 - Level 2
8 september	16.00	Lilly	Jennifer Laird	20 min	Pharma	27 - Level 2
8 september	16.20	Reciphar	Torkel Gren	20 min	Pharma	27 - Level 2
8 september	16.40	Grunenthal	Philipp Von Gallwitz	20 min	Pharma	27 - Level 2
8 september	17.00	Greater Helsinki Promotion	Juho Pirinen	5 min	Public	27 - Level 2
8 september	17.07	Turku Science Park	Tero Karhi	5 min	Public	27 - Level 2
8 september	17.15	Acreo Swedish ICT	Sara Bogren	5 min	MedTech	27 - Level 2
8 september	17.22	Superecg	Tuomas Harju	5 min	MedTech	27 - Level 2
8 september	17.30	Invest In Toulouse	Silvia Ferrari	5 min	Public	27 - Level 2
8 september	17.37	Projektsupport S-O	Anna Larsson	5 min	Services	27 - Level 2
8 september	17.45	Scandinavian Biopharma	Björn Sjöstrand	12 min	Vaccines	27 - Level 2



## 9 SEPTEMBER ROOM 26 -LEVEL 2

Date	Time	Company	Presenter Name	Presentation	Specialty	Location
9 september	8.30	Neurotar	Katja Karelina	12 min	Drug Development	26 - Level 2
9 september	8.45	Pre Diagnostics	Håkon Sæterøy	12 min	Drug Development	26 - Level 2
9 september	9.00	Vicore Pharma	Björn Dahlöf	12 min	Drug Development	26 - Level 2
9 september	9.15	Xspray Microparticles	Per Andersson	12 min	Drug Development	26 - Level 2
9 september	9.30	Apim Therapeutics	Kostas Alevizopoulos	12 min	Drug Development Oncology	26 - Level 2
9 september	9.45	Cormorant Pharmaceuticals	Maarten De Chateau	12 min	Drug Development Oncology	26 - Level 2
9 september	10.00	Lytix Biopharma	Unni Hjelmaas	12 min	Drug Development Oncology	26 - Level 2
9 september	10.15	Oncos Therapeutics	Frans Wuite	12 min	Drug Development Oncology	26 - Level 2
9 september	10.30	Vaccibody	Ole Henrik Brekke	12 min	Drug Development Oncology	26 - Level 2
9 september	10.45	CR Competence	Anna Stenstam	12 min	CRO	26 - Level 2
9 september	11.00	Delsitech	Lasse Leino	12 min	CRO	26 - Level 2
9 september	11.15	Integrated DNA Technologies	John Havens	12 min	CRO	26 - Level 2
9 september	11.30	Ossdsign	Bo Qwarnström	12 min	Drug Development	26 - Level 2
9 september	11.45	Link Medical	Ola Gudmundsen	12 min	CRO	26 - Level 2
9 september	12.00	Oncovet Clinical Research	Matthieu Dubruque	12 min	CRO	26 - Level 2
9 september	12.15	Pelago Bioscience	Michael Dabrowski	12 min	CRO	26 - Level 2



## PRESENTERS – WHERE AND WHEN

### 9 SEPTEMBER ROOM 27 -LEVEL 2

Date	Time	Company	Presenter Name	Presentation	Specialty	Location
9 september	8.30	Promega Biotech	Patrick Van De Velde	12 min	CRO	27 - Level 2
9 september	8.45	TFS	Jan Hellqvist	12 min	CRO	27 - Level 2
9 september	9.00	Aseptic Technologies	Olga Bukatova	12 min	MedTech	27 - Level 2
9 september	9.15	Bone Index Finland	Ossi Riekkinen	12 min	MedTech	27 - Level 2
9 september	9.30	Ebs Technologies	Ulf Pommerening	12 min	MedTech	27 - Level 2
9 september	9.45	Debiopharm International	Armelle Gaussin	12 min	Pharma	27 - Level 2
9 september	10.00	Avalon Health Economics	Cara Scheibling	12 min	Services	27 - Level 2
9 september	10.15	Genohm	Martijn Devisscher	12 min	Services	27 - Level 2
9 september	10.30	Photo Dynamic Therapy	Günther Hofmann	12 min	Services	27 - Level 2
9 september	10.45	SGS	Colin Crowley	12 min	Services	27 - Level 2
9 september	11.00	Johnson & Johnson	Anna Enzerink	20 min	Pharma	27 - Level 2
9 september	11.20	Novo Nordisk	Anand Gautam	20 min	Pharma	27 - Level 2
9 september	12.00	Roche	Maria Bobadilla	20 min	Pharma	27 - Level 2
9 september	14.00	AbbVie	Norbert Steinbach	20 min	Pharma	27 - Level 2
9 september	14.20	Bristol-Myers Squibb	Donnie McGrath	20 min	Pharma	27 - Level 2
9 september	14.40	Astrazeneca	Jane Buus Laursen	20 min	Pharma	27 - Level 2

## 62 EXHIBITORS LIST

Organization - Company	Stand n°
Biomeva	A1
VBU - Dechema	A2
Medipan	A3
Sinensis	A4
Crown	A5
Avestin - Milmedtek	A6
Genohm	A7
IRW	A8
Venture Valuation	A9
Life Science Nation	A10
Quintiles	B1
World Courier	B2
SGS	B3
BIA Separations	B4
Valea	B5
SP Technical Research Institute of Sweden	B6
France	C0
Cancer Bio Santé	C0
Cancer Campus	C0
Life Science Nord	C1
Belgium	C2
Awex	C2
BioWin	C2
Flanders Invest & Trade	C2
SwissBiotech	C3
Stockholm Business Region Development	C4
NanoMed North	C5
SwedNanoTech	C5

## EXHIBITORS LIST

Life Science Foresight Institute	C5
Science Parks Sweden	C6
Karolinska Institute Science Park	C6
Medeon Science Park	C6
Sahlgrenska Science Park	C6
Karolinska Innovations	C7
Recipharm	D1
Finland	D2
Admescope	D2
BioFinland	D2
BioTurku	D2
Biovian	D2
Finnish BioIndustries	D2
Helsinki Business Hub	D2
Innomedica	D2
Pharmatory	D2
Stockholm Life	D3
Stockholm Uppsala	D3
Stockholm Science City	D3
UppsalaBIO	D3
Uppsala Innovation Centre	D3
Uppsala University Innovation	D3
Innovation Akademiska	D3
Swedish BioPharma Industries	D4
LIF	D4
SwedenBIO	D4
Göteborg	D5
Business Region Göteborg	D5
GU Holding	D5
Göteborg & Co	D5
NextPharma	D6

## 64 EXHIBITORS LIST

Pfizer	E1
Invest in Skane	E2
Denmark	E3
Biopeople	E3
Copenhagen Capacity	E3
Dansk Biotek	E3
Business Sweden	E4
UKTI	E5
Norway	F1
Innovation Norway	F1
Inven2	F1
Nansen Neurosciences Network	F1
Oslo Cancer Cluster	F1
Nordic Medical Product Agencies	F2
FIMEA	F2
MPA	F2
NOMA	F2
DHMA	F2
Spain	F3
ICEX Invest in Spain	F3
Asebio	F3
Link Medical	G1
DNE Pharma Holding	G2

**partnering360®**  
more connections – more opportunities



**Watchlist**



**Profile**



**Search**



**Blog**

100% partnering, 360° engagement.

Companies, assets, and Insight. Everything leads to partnering.

[www.partnering360.com](http://www.partnering360.com)

7<sup>th</sup> Annual International Partnering Conference

**BIOPHARM  
AMERICA™ 2014**

**WHERE PARTNERSHIPS START**

**SEPTEMBER 22-24, 2014  
BOSTON, MA, USA**

**BOSTON MARRIOTT COPLEY PLACE**

Please enter **DE021\_BPA14\_NLSD** in the registration code field when registering.

Find out more: [www.ebdgroup.com/bpa](http://www.ebdgroup.com/bpa)

Producer

**EBD  
GROUP**

Hosted by

**MassBio**  
PHARMACEUTICALS & BIOTECHNOLOGY COUNCIL



---

Bronze Sponsors



---

Premium Media and Partnering Partners



---

Partnering and Media Supporters



## Gold Sponsors

**Arthur D Little**



**Bristol-Myers Squibb**



**chairmanship**  
2014|2015



Switzerland.



**EY** Building a better  
working world



Interreg IVA  
ÖRESUND – KATTEGAT – SKAGERRAK



THE EUROPEAN UNION  
The European Regional  
Development Fund

**invest** in skåne  
part of business region skåne



**LIF**

The research-based  
pharmaceutical industry

**Lilly**



**LÄKEMEDELVERKET**  
MEDICAL PRODUCTS AGENCY



**Statens legemiddelverk**  
Norwegian Medicines Agency



**Stockholm**  
Business Region  
Development



Swiss-Swedish  
Innovation  
Initiative



**2014** Nordic  
Life  
Science  
Days  
**NLSDAYS**



## Silver Sponsors

abbvie  
HealthCap

**BioWin**  
THE HEALTH CLUSTER OF WALLONIA



 Industrifonden

*Johnson & Johnson*  
INNOVATION


 **LIFE SCIENCE  
NATION**  
Connecting Products, Services & Capital

 **MSD** **NASDAQ OMX**<sup>®</sup>

  
novo nordisk<sup>®</sup>

**Recipharm**  
good for business

  
**SVEANOR**  
FASTIGHETER



# Save the date

Nordic Life Science Days 2015 in Stockholm, September 8-10

Welcome!

Wojtek Gurak

Produced by

The Swedish Life Science Industry Organization

**sweden**BIO